================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                          -----------------------------

                                    FORM 8-K
                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report:

                        (Date of earliest event reported)

                                  May 13, 2005

                          ----------------------------

                               CHISTE CORPORATION
               (Exact name of registrant as specified in charter)


                                     Nevada
         (State or other Jurisdiction of Incorporation or Organization)


       0-32065                                           86-0965692
(Commission File Number)                     (IRS Employer Identification No.)

                                 936A Beachland
                               Boulevard, Suite 13
                              Vero Beach, FL 32963
                         (Address of Principal Executive
                              Offices and zip code)

                                 (772) 231-7544
                             (Registrant's telephone
                          number, including area code)

                                       N/A
          (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17
      CFR 240.14a-12(b))

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

================================================================================
<PAGE>

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

      Information included in this Form 8-K may contain forward-looking
statements within the meaning of Section 27A of the Securities Act and Section
21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
This information may involve known and unknown risks, uncertainties and other
factors which may cause Chiste's and HydroGen's actual results, performance or
achievements to be materially different from future results, performance or
achievements expressed or implied by any forward-looking statements.
Forward-looking statements, which involve assumptions and describe Chiste's and
HydroGen's future plans, strategies and expectations, are generally identifiable
by use of the words "may," "will," "should," "expect," "anticipate," "estimate,"
"believe," "intend" or "project" or the negative of these words or other
variations on these words or comparable terminology. Forward-looking statements
are based on assumptions that may be incorrect, and there can be no assurance
that any projections or other expectations included in any forward-looking
statements will come to pass. Chiste's and HydroGen's actual results could
differ materially from those expressed or implied by the forward-looking
statements as a result of various factors. Except as required by applicable
laws, Chiste undertakes no obligation to update publicly any forward-looking
statements for any reason, even if new information becomes available or other
events occur in the future.

Section 1 - Registrants' Business and Operations

Item 1.01  Entry into a Material Definitive Agreement.

      On May 13, 2005, Chiste Corporation, a Nevada corporation ("Chiste"),
entered into an Exchange Agreement ("Exchange Agreement") with HydroGen, LLC, an
Ohio limited liability company ("HydroGen"), certain members of HydroGen owning
approximately 69.7% of HydroGen's currently outstanding membership interests,
and Keating Reverse Merger Fund, LLC ("KRM Fund"). Under the Exchange Agreement,
Chiste will, at closing, acquire all of the outstanding membership interests of
HydroGen ("Interests") from the members of HydroGen ("HydroGen Members"), and
the HydroGen Members will contribute all of their Interests to Chiste. In
exchange, Chiste will issue to the HydroGen Members shares of Series B
Convertible Preferred Stock, par value $0.001 per share, of Chiste ("Preferred
Shares"), with each Preferred Share being convertible into 185.35215 shares of
Chiste's common stock ("Conversion Shares"). As a condition of the closing of
the transactions under the Exchange Agreement ("Closing"), all of the current
members of HydroGen must execute or join the Exchange Agreement and agree to
receive Preferred Shares in exchange for their Interests. Following the Closing,
HydroGen, LLC will continue as a wholly-owned subsidiary of Chiste.

      Among the conditions to the Closing of the exchange transaction
("Exchange"), HydroGen will raise a minimum of $5,000,000 and a maximum of
$10,000,000 in a private placement offering of Interests ("Placement") to
accredited investors ("HydroGen Investors"). The holders of HydroGen's
$2,000,000 of outstanding convertible bridge notes may convert their principal
balances into Interests under the private placement, but any conversions will
not count towards the minimum offering amount.


                                       2
<PAGE>

      The HydroGen Investors will be required to execute or join the Exchange
Agreement as part of their investment and, accordingly, the Interests received
by the HydroGen Investors will be exchanged for Preferred Shares pursuant to the
terms of the Exchange Agreement.

      The consummation of the Placement is contingent on the completion of the
Exchange and an additional $7,000,000 being invested in Preferred Shares of
Chiste, promptly following the Exchange, by certain institutional investors
("Institutional Investors"). The proposed investment by the Institutional
Investors ("Investment") will involve the purchase of Preferred Shares directly
from Chiste promptly after the Exchange, and the purchase price of the Preferred
Shares received by HydroGen Investors in the Placement as a result of the
exchange of their Interests will be the same as the purchase price of the
Preferred Shares paid by the Institutional Investors in the Investment.

      Upon completion of the Exchange, the Placement and the Investment, the
Preferred Shares issued by Chiste to the HydroGen Members, the HydroGen
Investors and the Institutional Investors will represent in the aggregate
95.175% of Chiste's issued and outstanding shares of common stock on a fully
diluted and as-converted basis (without giving effect to certain outstanding
Chiste warrants that will expire June 30, 2005). Accordingly, the current
stockholders of Chiste will own 4.825% of the outstanding common stock (or,
9,396,629 shares of Chiste common stock) immediately after completion of these
transactions on a fully diluted and as-converted basis.

      The issuance of the Preferred Shares in connection with the Exchange to
the HydroGen Members and the HydroGen Investors and, upon conversion, the shares
of Chiste common stock underlying the Preferred Shares, is intended to be exempt
from registration under the Securities Act of 1933, as amended (the "Securities
Act"), pursuant to Section 4(2) thereof. The Investment is being offered
pursuant to an exemption from registration contained in Regulation D, only to
accredited investors. The Preferred Shares and the shares of Chiste common stock
underlying the Preferred Shares may not be offered or sold in the United States
unless they are registered under the Securities Act, or an exemption from the
registration requirements of the Securities Act is available. No registration
statement covering these securities has been filed with the United States
Securities and Exchange Commission ("Commission") or with any state securities
commission in respect of this Offering. However, Chiste has agreed to register
for public re-sale the common stock underlying the Preferred Stock issued in the
Exchange held by certain HydroGen Members (none of which are the officers,
directors or employees of HydroGen), the HydroGen Investors and the
Institutional Investors.

      Chiste is presently authorized under its Certificate of Incorporation to
issue 65,000,000 shares of common stock, par value $0.001 per share, and
10,000,000 shares of preferred stock, par value $0.001 per share. Of the
10,000,000 shares of preferred stock authorized, 1,500,000 shares will be
designated as Series B Convertible Preferred Stock pursuant to a certificate of
designations ("Certificate of Designations"), which will be approved by Chiste's
board of directors, and filed with and accepted by, the Secretary of State of
the State of Nevada prior to the Closing of the Exchange. Currently, Chiste has
9,396,629 shares of common stock issued and outstanding and no shares of
preferred stock issued and outstanding.

      Under the terms of the Exchange Agreement, all of the outstanding
Interests held by HydroGen Members and HydroGen Investors will be exchanged for
Preferred Shares. Each Preferred Share will be convertible into 185.35215 shares
of Chiste's common stock (the "Conversion Rate"). The Preferred Shares will
immediately and automatically be converted into shares of Chiste's common stock
(the "Mandatory Conversion") upon the approval by a majority of Chiste's
stockholders (voting together on an as-converted-to-common-stock basis),
following the Exchange and the Investment, of a 1 for 25 reverse stock split of
Chiste's outstanding common stock ("Reverse Split").


                                       3
<PAGE>

      The holders of shares of Series B Preferred Stock (including Institutional
Investors acquiring such Preferred Shares following ht Exchange) will be
entitled to vote together with the holders of the common stock, as a single
class, upon all matters submitted to holders of common stock for a vote. Each
share of Series B Preferred Stock will carry a number of votes equal to the
number of shares of common stock issuable as if converted at the record date. As
such, immediately following the Exchange and the Investment, the HydroGen
Members, HydroGen Investors and the Institutional Investors will have 95.175% of
the total combined voting power of all classes of Chiste stock entitled to vote.

      Upon Mandatory Conversion of the Preferred Shares, and subject to an
adjustment of the Conversion Rate as a result of the Reverse Split, the HydroGen
Members, HydroGen Investors and the Institutional Investors will, in the
aggregate, receive approximately 7,414,086 shares of Chiste's common stock,
representing 95.175% of the outstanding shares of Chiste's common stock
immediately following the Mandatory Conversion on a fully diluted basis (without
giving effect to the Chiste warrants expiring June 30, 2005). The existing
stockholders of Chiste will, following the Mandatory Conversion and Reverse
Split, own approximately 375,865 shares of Chiste's common stock, representing
4.825% of the outstanding shares of common stock on a fully diluted basis.

      In connection with the Reverse Split, Chiste's board of directors may, in
its discretion, provide special treatment to certain Chiste stockholders to
preserve round lot holders (i.e., holders owning at least 100 shares) after the
Reverse Split. In the event Chiste's board determines to provide such special
treatment, Chiste stockholders holding 2,500 or fewer shares of common stock but
at least 100 shares of common stock will receive 100 shares of common stock
after the Reverse Split, and persons holding less than 100 shares of common
stock would not be affected. The terms and conditions of special treatment
afforded to Chiste stockholders to preserve round lot stockholders, if any,
including the record dates for determining which stockholders may be eligible
for such special treatment, will be established in the discretion of Chiste's
board of directors.

      Effective as of the Closing of the Exchange transaction, and subject to
applicable regulatory requirements, including the preparation, filing and
distribution to the Chiste stockholders of a Schedule 14(f)-1 Notice to
Stockholders at least ten (10) days prior to Closing, Kevin R. Keating, Chiste's
current sole officer and director will resign, and the newly-appointed directors
of Chiste will consist of two member of HydroGen's current management, Leo
Blomen and Joshua Tosteson, two directors to be designated by Messrs. Blomen and
Tosteson, and one member to be designated by KRM Fund (the "KRM Designate"). KRM
Fund, certain HydroGen Members, the HydroGen Investors and the Institutional
Investors, such persons in the aggregate representing more than a majority of
the outstanding shares entitled to vote, have each agreed to vote their shares
of Chiste's voting securities: (i) to elect the KRM Designate to Chiste's board
for a period ranging from 90 days to one year following the Closing and to vote
for such other persons that may be designated by Messrs. Blomen and Tosteson to
fill any vacant position on the board of directors (other than KRM Designate),
and (ii) to approve the Reverse Split and the change of Chiste's corporate name
(collectively, the "Actions").


                                       4
<PAGE>

      In connection with the Exchange Agreement, from the signing of the
agreement until its termination or the consummation of the exchange transaction,
KRM Fund has entered into a voting agreement with HydroGen under which (i) it
agrees not to sell, pledge or otherwise dispose of any or all of its shares of
common stock of Chiste or deposit them in a voting trust or enter into any other
voting agreement, and it will vote or consent in favor of the adoption of the
Exchange Agreement and the exchange transaction, if necessary, and against any
merger, consolidation, sale of assets, recapitalization or other business
combination other than the transaction with HydroGen. KRM Fund has granted to
HydroGen a proxy in the event they do not take action to vote as provided above
so that HydroGen may act in its stead. Nothing in the voting agreement will
prevent any director of Chiste, whether an affiliate of KRM Fund or not, from
exercising its fiduciary duty under Nevada law.

      Additional information concerning Leo Blomen and Joshua Tosteson and the
other directors to be designated by the parties will be included in the Schedule
14(f)-1 Notice to Stockholders which will be filed with the SEC and mailed to
stockholders at least ten (10) days prior to the Closing of the Exchange.

      At or prior to the Closing, Chiste will also enter into a certain
financial advisory agreement with Keating Securities, LLC ("Keating
Securities"), a registered broker-dealer, under which Keating Securities will be
compensated by Chiste for its advisory services rendered to Chiste in connection
with the Exchange. The transaction advisory fee will be $325,000, with the
payment thereof being subject to the Closing of the Exchange.

      Each of Chiste and HydroGen has agreed to continue to operate their
business in the ordinary course prior to the Exchange. In addition, HydroGen is
able to pursue the Placement and take the actions necessary to effect the
Exchange and Chiste is able to pursue the Investment.

      Under the Exchange Agreement, each of Chiste and HydroGen has agreed to do
certain things, some of which are conditions to the exchange transaction. Each
company is obligated to (a) obtain all necessary approvals, which includes
approval by the members of HydroGen for various aspects of the transaction, (b)
HydroGen is required to obtain agreements from its members to exchange their
Interests and to amend all outstanding agreements to acquire Interests to
substitute shares of Preferred Stock or common stock of Chiste in connection
with any options, warrants and convertible securities and other agreements, (c)
HydroGen must enter into agreements to eliminate any existing pre-emptive rights
for Interests, (d) give the other access to the records and personnel to
complete due diligence review, (e) proceed expeditiously to undertake all
actions so as to be able to consummate the Exchange, (d) HydroGen must deliver
audited financial statements including a balance sheet as of December 31, 2004
and statements of operations, cash flows and stockholders' equity from inception
to December 31, 2004 and unaudited financial statements of HydroGen for the
quarter ended prior to the Closing, and (e) neither party will solicit or
initiate proposals from, provide information to or hold discussions with any
party concerning any sale of assets or any material portion of any capital stock
or any merger, consolidation, business combination, liquidation or similar
transaction, subject to the fiduciary obligations of directors generally.


                                       5
<PAGE>

      Consummation of the Exchange is conditioned upon the minimum amount of the
Placement being held in escrow and available at the time of the consummation of
the Exchange. Consummation of the Exchange is also contingent upon tax counsel
to HydroGen issuing its opinion that the transaction will not be taxable to the
holders of Interests (including the Interests sold in the Placement) pursuant to
Section 351 of the Internal Revenue Code. Hydrogen also will have entered into
employment agreements with its senior executives. The management persons will
have entered into a voting agreement, similar to that agreed to by the HydroGen
Investors in the Placement, to vote in favor of the Actions following the
Exchange and for the KRM Designate for a period of one year after the closing of
the Exchange. In addition to the foregoing conditions, the Exchange is
conditioned upon (i) preparation, filing and distribution to the Chiste
stockholders of a Schedule 14(f)-1 Notice to Stockholders, and (ii) continued
quotation of Chiste's common stock on the Over-the-Counter Bulletin Board.

      Except for the representations and warranties relating to the ownership of
the Interests (including the Interests sold in the Placement) which survive the
consummation of the Exchange, the representations and warranties of all the
parties to the Exchange Agreement do not survive the closing.

      The Exchange Agreement may be terminated as follows: (i) by mutual
consent, (ii) by either party if the Exchange is not consummated by June 15,
2005, (iii) by either party if the Exchange is prohibited by issuance of an
order, decree or ruling, (iv) by either party if the other is in material breach
of any representation, warranty, covenant or agreement, or (v) by Chiste if
HydroGen is not able to obtain the agreement of each HydroGen Member and each
HydroGen Investor to join in the Exchange Agreement and agree to transfer their
Interests to Chiste in the Exchange. In the event of termination, both parties
are responsible for their expenses, except that Chiste may retain a $50,000
deposit paid by HydroGen in the event that the termination is for a breach by
HydroGen or failure to obtain the agreement of all of the HydroGen Members to
join in the Exchange Agreement or convey their Interests.

      Because an integral part of the Exchange and a condition to the Placement
is the completion of the Investment in the Preferred Stock by the Institutional
Investors, which itself is contingent on the consummation of the Exchange and
the minimum amount being received under the Placement in escrow, the Investment
will be made after the Closing of the Exchange. The Investment must be
subscribed and funded within three days of the Closing of the Exchange. If the
Institutional Investors do not subscribe for $7,000,000 of Preferred Shares and
fund the subscription within such three day period, then the Exchange will be
rescinded, and the Placement cancelled with the escrowed subscriptions for
Interests returned to the HydroGen Investors, without interest or deduction.
Additionally, in the event of a rescission of the Exchange, all other aspects of
the Exchange will be cancelled and the HydroGen Members restored to their
relative ownership and positions in HydroGen and of Interests in HydroGen as it
was immediately prior to the Exchange.

      The directors of Chiste have approved the Exchange Agreement and the
transactions contemplated thereunder. The managers of HydroGen have approved the
Exchange Agreement and the transactions contemplated thereunder, and members
owning approximately 69.7% of HydroGen's outstanding Interests have executed the
Exchange Agreement . The parties expect the closing of the transactions under
the Exchange Agreement to occur on or about June 15, 2005. However, there can be
no assurances that the Exchange will be completed.


                                       6
<PAGE>

      On March 28, 2005, in its Current Report on Form 8-K dated March 24, 2005,
Chiste reported the execution of a letter of intent to acquire HydroGen.

      Kevin R. Keating is the father of the principal member of Keating
Investments, LLC. Keating Investments, LLC is the managing member of KRM Fund,
which is the current majority stockholder of Chiste, and Keating Securities,
LLC, the registered broker-dealer affiliate of Keating Investments, LLC. Kevin
R. Keating is not affiliated with and has no equity interest in Keating
Investments, LLC, KRM Fund or Keating Securities, LLC and disclaims any
beneficial interest in the shares of Chiste's common stock owned by KRM Fund.
Similarly, Keating Investments, LLC, KRM Fund and Keating Securities, LLC
disclaim any beneficial interest in the shares of Chiste's common stock
currently owned by Kevin R. Keating.

Business of Chiste

      Chiste is currently a public "shell" company with nominal assets whose
sole business has been to identify, evaluate and investigate various companies
with the intent that, if such investigation warrants, a reverse merger
transaction be negotiated and completed pursuant to which Chiste would acquire a
target company with an operating business with the intent of continuing the
acquired company's business as a publicly held entity.

Business of HydroGen

      HydroGen is a development stage company, organized in 2001 and established
as a limited liability company in January 2002. One of the founding members
contributed various intellectual property assets and technologies which it had
acquired from Westinghouse Electric Corporation, some of which were developed
under a Department of Energy (DOE) sponsored research and development program.

      HydroGen was established to be a developer of multi-megawatt fuel cell
systems utilizing its proprietary 400 kilowatt (kW) phosphoric acid fuel cell
(PAFC) technology. HydroGen is positioning itself to compete in the rapidly
growing distributed generation market, by offering complete fuel cell systems in
the 6-30 megawatt (MW) range at prices that HydroGen's management believes will
be competitive with incumbent generating technologies in this size class, and
significantly lower than other fuel cell technologies.

      HydroGen's technology and approach are unique because air-cooled PAFC fuel
cells are used, and the individual fuel cell stacks are detached from the
hydrogen source. HydroGen's management believes this approach will result in
significant cost savings, since air-cooled stacks are inherently simple to
manufacture, and because HydroGen's fuel cell power plants can utilize either
mature, large-scale hydrogen plant technology or existing hydrogen
infrastructure to supply hydrogen to the fuel cell stacks.


                                       7
<PAGE>

      HydroGen's products provide close to zero-emission, net water-generating,
reliable, high-quality electric power from hydrogen. These products address
directly the problems associated with the current inefficient, centralized,
combustion-based energy system by offering economically competitive fuel cell
systems that will accelerate market entry of the "hydrogen economy."

      Target markets for HydroGen systems include the general industrial
cogeneration market, grid support and distributed generation for utilities,
educational and municipal institutions seeking clean power, and niche markets
associated with the existing global hydrogen production infrastructure. HydroGen
has done extensive market research, supported in part by the DOE, and is working
in partnership with major industrial gas companies, utilities, chemicals
companies, and select government facilities to identify project locations for
HydroGen's early series of units.

      Hydrogen's intellectual property includes certain rights and manufacturing
assets for the 400 kW, air-cooled PAFC technology developed by Westinghouse and
represented by a revocable, non-exclusive license to use all technology
developed pursuant to the DOE sponsored program. In addition, Westinghouse
undertook its own development of module designs and manufacturing plans, and
constructed a manufacturing facility and working prototype module. During this
manufacturing and prototype program, Westinghouse privately developed recipes,
processes and plans for designing and manufacturing phosphoric acid fuel cells.
That intellectual property, maintained by Westinghouse as trade secrets, has
been transferred to the HydroGen along with all of Westinghouse's rights to the
technology developed under the DOE research and development program, and has
since been maintained as closely held secrets.

      Most of HydroGen's core intellectual property has been maintained as trade
secrets, which are kept in the form of drawings, recipes, process descriptions
and other writings. HydroGen has kept, and intends to continue to keep, these
secrets closely guarded, distributing them on a need to know basis only, and
implementing strict confidentiality and non-use agreements when disclosure is
necessary.

      Although most of the core technology has been maintained as trade secrets,
Westinghouse applied for and received patents from time to time related to the
technologies. These were all subsequently assigned to the DOE. A non-exclusive
license to use these patents has been assigned, to HydroGen. Although, most of
the DOE patents have expired or were allowed by the DOE to lapse, the DOE did
maintain four key patents, which remain in effect today. HydroGen has submitted
an application to the DOE for an exclusive license for the continuing patents.
The application is now under DOE review, which review includes a 30 day public
comment period before the DOE can grant the exclusive license. If the DOE is
unable to grant the exclusive license, HydroGen will be able to continued use
the patents on a non-exclusive, licensed basis.

      HydroGen occupies approximately 30,000 square feet of manufacturing
facilities in Jefferson Hills, PA (near Pittsburgh), and operates them as its
pilot manufacturing plant. Hydrogen intends to use some of the capital it
proposes to raise to increase the production capacity of this facility from the
current 2MW/year capacity to 4-5 MW/year. The facility includes production
equipment for the electrodes, graphite plates, stacks, and various non-repeating
components of the fuel cells and fuel cell stacks. The long-term plan is to
expand production by deploying an automated manufacturing plant capable
initially of producing 25MW (62 modules) per year, and later 100MW (250 modules)
per year.


                                       8
<PAGE>

      HydroGen's business model is to sell on a turnkey basis 6-30MW power
plants, based on a standardized 2MW power island consisting of five of its 400kW
modules. Additionally, HydroGen plans to generate recurring revenues from the
sale of operations and maintenance services and ongoing lease revenues for the
400kW modules which must be replaced every 40,000 hours initially.

      There are many risks associated with the business of HydroGen, some of
which are indicated below. HydroGen is a development stage company with a
limited operating history on which it may be analyzed. HydroGen will be exposed
to all the risks of establishing a new business in a developmental field,
including finding appropriate personnel, managing development of its products
and marketing efforts, and managing its capital resources and future funding.
The intellectual property rights held by Hydrogen may require additional
development which may require additional unplanned expense, and solving
unanticipated engineering problems. HydroGen does not have experience in
manufacturing fuel cell power plants on a commercial basis, and therefore, it
may not be able to achieve market driven production standards and production
volumes required to operate cost effectively. The principal intellectual
property rights were developed by Westinghouse and the DOE, and there are some
uncertainties as to the sufficiency and scope of those rights evidenced in the
change of assignments and licenses. Others may assert interests in the HydroGen
intellectual property rights which may impede or limit HydroGen's ability to
capitalize on them. There could be barriers to obtaining customers because
electric utility companies charge fees to industrial customers for disconnecting
from the grid, for using less electricity or using the grid as a backup source.
Because the HydroGen technology is new, it may not be readily accepted in the
market place. HydroGen will require substantial capital to fully develop its
business plan, which capital may not be available in the future or might be
available only on terms that are not economic or subject to many conditions and
limitations. From time to time and for various aspects of its operations,
HydroGen will need to obtain permits and other government approvals which if not
obtained on a timely basis will cause additional costs or limit or prevent
required operations. There is much competition in the energy industry from
conventional sources (i.e. combustion power generation manufacturers and
renewable energy developers) and new alternative technologies (i.e. molten
carbonate fuel cells, solid oxide fuel cells, and biomass energy sources), all
of which will impact on HydroGen's ability to obtain a market presence and win
customers. Any one or more of the above identified risks may affect the business
operations adversely or require capital that may not be available when required,
with the effect of an adverse economic impact on HydroGen and a loss of value in
an investment in the parent holding company.

      Item 9.01 Financial Statements and Exhibits.

      (a) Financial statements of business acquired. None.

      (b) Pro forma financial information. None.

      (c) Exhibits.

          2.2     Exchange Agreement by and between Chiste Corporation,
                  HydroGen, LLC, and certain members of HydroGen, LLC dated May
                  13, 2005.


                                       9
<PAGE>

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934,
Chiste Corporation has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                Chiste Corporation


Date: May 18, 2005            By: /s/ Kevin R. Keating
                                  ---------------------------------------------
                                  Kevin R. Keating, President and Sole Director


                                       10
<PAGE>

                                  EXHIBIT INDEX


Exhibit Number                                  Description of Exhibit
--------------                                  ----------------------

     2.2                                   Exchange Agreement by and between
                                           Chiste Corporation, HydroGen, LLC,
                                           and certain members of HydroGen, LLC
                                           dated May 13, 2005.


                                       11
{"company-data": {"conformed-name": "CHISTE CORP", "cik": "0001124394", "assigned-sic": "3510", "irs-number": "860965692"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-32065", "film-number": "05841776"}, "business-address": {"street1": "14647 S. 50TH STREET", "street2": "SUITE 130", "city": "PHOENIX", "state": "AZ", "zip": "85044-6475", "phone": "480-759-9400"}, "mail-address": {"street1": "14647 S. 50TH STREET", "street2": "SUITE 130", "city": "PHOENIX", "state": "AZ", "zip": "85044-6475"}, "former-company": {"former-conformed-name": "DYNA CAM", "date-changed": "20000921"}}
================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                          -----------------------------

                                    FORM 8-K
                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report:

                        (Date of earliest event reported)

                                  May 13, 2005

                          ----------------------------

                               CHISTE CORPORATION
               (Exact name of registrant as specified in charter)

                                     Nevada
         (State or other Jurisdiction of Incorporation or Organization)

       0-32065                                           86-0965692
(Commission File Number)                     (IRS Employer Identification No.)

                                 936A Beachland
                               Boulevard, Suite 13
                              Vero Beach, FL 32963
                         (Address of Principal Executive
                              Offices and zip code)

                                 (772) 231-7544
                             (Registrant's telephone
                          number, including area code)

                                       N/A
          (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17
      CFR 240.14a-12(b))

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

================================================================================
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

      Information included in this Form 8-K may contain forward-looking
statements within the meaning of Section 27A of the Securities Act and Section
21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
This information may involve known and unknown risks, uncertainties and other
factors which may cause Chiste's and HydroGen's actual results, performance or
achievements to be materially different from future results, performance or
achievements expressed or implied by any forward-looking statements.
Forward-looking statements, which involve assumptions and describe Chiste's and
HydroGen's future plans, strategies and expectations, are generally identifiable
by use of the words "may," "will," "should," "expect," "anticipate," "estimate,"
"believe," "intend" or "project" or the negative of these words or other
variations on these words or comparable terminology. Forward-looking statements
are based on assumptions that may be incorrect, and there can be no assurance
that any projections or other expectations included in any forward-looking
statements will come to pass. Chiste's and HydroGen's actual results could
differ materially from those expressed or implied by the forward-looking
statements as a result of various factors. Except as required by applicable
laws, Chiste undertakes no obligation to update publicly any forward-looking
statements for any reason, even if new information becomes available or other
events occur in the future.

Section 1 - Registrants' Business and Operations

Item 1.01  Entry into a Material Definitive Agreement.

      On May 13, 2005, Chiste Corporation, a Nevada corporation ("Chiste"),
entered into an Exchange Agreement ("Exchange Agreement") with HydroGen, LLC, an
Ohio limited liability company ("HydroGen"), certain members of HydroGen owning
approximately 69.7% of HydroGen's currently outstanding membership interests,
and Keating Reverse Merger Fund, LLC ("KRM Fund"). Under the Exchange Agreement,
Chiste will, at closing, acquire all of the outstanding membership interests of
HydroGen ("Interests") from the members of HydroGen ("HydroGen Members"), and
the HydroGen Members will contribute all of their Interests to Chiste. In
exchange, Chiste will issue to the HydroGen Members shares of Series B
Convertible Preferred Stock, par value $0.001 per share, of Chiste ("Preferred
Shares"), with each Preferred Share being convertible into 185.35215 shares of
Chiste's common stock ("Conversion Shares"). As a condition of the closing of
the transactions under the Exchange Agreement ("Closing"), all of the current
members of HydroGen must execute or join the Exchange Agreement and agree to
receive Preferred Shares in exchange for their Interests. Following the Closing,
HydroGen, LLC will continue as a wholly-owned subsidiary of Chiste.

      Among the conditions to the Closing of the exchange transaction
("Exchange"), HydroGen will raise a minimum of $5,000,000 and a maximum of
$10,000,000 in a private placement offering of Interests ("Placement") to
accredited investors ("HydroGen Investors"). The holders of HydroGen's
$2,000,000 of outstanding convertible bridge notes may convert their principal
balances into Interests under the private placement, but any conversions will
not count towards the minimum offering amount.

                                       2
The HydroGen Investors will be required to execute or join the Exchange
Agreement as part of their investment and, accordingly, the Interests received
by the HydroGen Investors will be exchanged for Preferred Shares pursuant to the
terms of the Exchange Agreement.

      The consummation of the Placement is contingent on the completion of the
Exchange and an additional $7,000,000 being invested in Preferred Shares of
Chiste, promptly following the Exchange, by certain institutional investors
("Institutional Investors"). The proposed investment by the Institutional
Investors ("Investment") will involve the purchase of Preferred Shares directly
from Chiste promptly after the Exchange, and the purchase price of the Preferred
Shares received by HydroGen Investors in the Placement as a result of the
exchange of their Interests will be the same as the purchase price of the
Preferred Shares paid by the Institutional Investors in the Investment.

      Upon completion of the Exchange, the Placement and the Investment, the
Preferred Shares issued by Chiste to the HydroGen Members, the HydroGen
Investors and the Institutional Investors will represent in the aggregate
95.175% of Chiste's issued and outstanding shares of common stock on a fully
diluted and as-converted basis (without giving effect to certain outstanding
Chiste warrants that will expire June 30, 2005). Accordingly, the current
stockholders of Chiste will own 4.825% of the outstanding common stock (or,
9,396,629 shares of Chiste common stock) immediately after completion of these
transactions on a fully diluted and as-converted basis.

      The issuance of the Preferred Shares in connection with the Exchange to
the HydroGen Members and the HydroGen Investors and, upon conversion, the shares
of Chiste common stock underlying the Preferred Shares, is intended to be exempt
from registration under the Securities Act of 1933, as amended (the "Securities
Act"), pursuant to Section 4(2) thereof. The Investment is being offered
pursuant to an exemption from registration contained in Regulation D, only to
accredited investors. The Preferred Shares and the shares of Chiste common stock
underlying the Preferred Shares may not be offered or sold in the United States
unless they are registered under the Securities Act, or an exemption from the
registration requirements of the Securities Act is available. No registration
statement covering these securities has been filed with the United States
Securities and Exchange Commission ("Commission") or with any state securities
commission in respect of this Offering. However, Chiste has agreed to register
for public re-sale the common stock underlying the Preferred Stock issued in the
Exchange held by certain HydroGen Members (none of which are the officers,
directors or employees of HydroGen), the HydroGen Investors and the
Institutional Investors.

      Chiste is presently authorized under its Certificate of Incorporation to
issue 65,000,000 shares of common stock, par value $0.001 per share, and
10,000,000 shares of preferred stock, par value $0.001 per share. Of the
10,000,000 shares of preferred stock authorized, 1,500,000 shares will be
designated as Series B Convertible Preferred Stock pursuant to a certificate of
designations ("Certificate of Designations"), which will be approved by Chiste's
board of directors, and filed with and accepted by, the Secretary of State of
the State of Nevada prior to the Closing of the Exchange. Currently, Chiste has
9,396,629 shares of common stock issued and outstanding and no shares of
preferred stock issued and outstanding.

      Under the terms of the Exchange Agreement, all of the outstanding
Interests held by HydroGen Members and HydroGen Investors will be exchanged for
Preferred Shares. Each Preferred Share will be convertible into 185.35215 shares
of Chiste's common stock (the "Conversion Rate"). The Preferred Shares will
immediately and automatically be converted into shares of Chiste's common stock
(the "Mandatory Conversion") upon the approval by a majority of Chiste's
stockholders (voting together on an as-converted-to-common-stock basis),
following the Exchange and the Investment, of a 1 for 25 reverse stock split of
Chiste's outstanding common stock ("Reverse Split").

                                       3
The holders of shares of Series B Preferred Stock (including Institutional
Investors acquiring such Preferred Shares following ht Exchange) will be
entitled to vote together with the holders of the common stock, as a single
class, upon all matters submitted to holders of common stock for a vote. Each
share of Series B Preferred Stock will carry a number of votes equal to the
number of shares of common stock issuable as if converted at the record date. As
such, immediately following the Exchange and the Investment, the HydroGen
Members, HydroGen Investors and the Institutional Investors will have 95.175% of
the total combined voting power of all classes of Chiste stock entitled to vote.

      Upon Mandatory Conversion of the Preferred Shares, and subject to an
adjustment of the Conversion Rate as a result of the Reverse Split, the HydroGen
Members, HydroGen Investors and the Institutional Investors will, in the
aggregate, receive approximately 7,414,086 shares of Chiste's common stock,
representing 95.175% of the outstanding shares of Chiste's common stock
immediately following the Mandatory Conversion on a fully diluted basis (without
giving effect to the Chiste warrants expiring June 30, 2005). The existing
stockholders of Chiste will, following the Mandatory Conversion and Reverse
Split, own approximately 375,865 shares of Chiste's common stock, representing
4.825% of the outstanding shares of common stock on a fully diluted basis.

      In connection with the Reverse Split, Chiste's board of directors may, in
its discretion, provide special treatment to certain Chiste stockholders to
preserve round lot holders (i.e., holders owning at least 100 shares) after the
Reverse Split. In the event Chiste's board determines to provide such special
treatment, Chiste stockholders holding 2,500 or fewer shares of common stock but
at least 100 shares of common stock will receive 100 shares of common stock
after the Reverse Split, and persons holding less than 100 shares of common
stock would not be affected. The terms and conditions of special treatment
afforded to Chiste stockholders to preserve round lot stockholders, if any,
including the record dates for determining which stockholders may be eligible
for such special treatment, will be established in the discretion of Chiste's
board of directors.

      Effective as of the Closing of the Exchange transaction, and subject to
applicable regulatory requirements, including the preparation, filing and
distribution to the Chiste stockholders of a Schedule 14(f)-1 Notice to
Stockholders at least ten (10) days prior to Closing, Kevin R. Keating, Chiste's
current sole officer and director will resign, and the newly-appointed directors
of Chiste will consist of two member of HydroGen's current management, Leo
Blomen and Joshua Tosteson, two directors to be designated by Messrs. Blomen and
Tosteson, and one member to be designated by KRM Fund (the "KRM Designate"). KRM
Fund, certain HydroGen Members, the HydroGen Investors and the Institutional
Investors, such persons in the aggregate representing more than a majority of
the outstanding shares entitled to vote, have each agreed to vote their shares
of Chiste's voting securities: (i) to elect the KRM Designate to Chiste's board
for a period ranging from 90 days to one year following the Closing and to vote
for such other persons that may be designated by Messrs. Blomen and Tosteson to
fill any vacant position on the board of directors (other than KRM Designate),
and (ii) to approve the Reverse Split and the change of Chiste's corporate name
(collectively, the "Actions").

                                       4
In connection with the Exchange Agreement, from the signing of the
agreement until its termination or the consummation of the exchange transaction,
KRM Fund has entered into a voting agreement with HydroGen under which (i) it
agrees not to sell, pledge or otherwise dispose of any or all of its shares of
common stock of Chiste or deposit them in a voting trust or enter into any other
voting agreement, and it will vote or consent in favor of the adoption of the
Exchange Agreement and the exchange transaction, if necessary, and against any
merger, consolidation, sale of assets, recapitalization or other business
combination other than the transaction with HydroGen. KRM Fund has granted to
HydroGen a proxy in the event they do not take action to vote as provided above
so that HydroGen may act in its stead. Nothing in the voting agreement will
prevent any director of Chiste, whether an affiliate of KRM Fund or not, from
exercising its fiduciary duty under Nevada law.

      Additional information concerning Leo Blomen and Joshua Tosteson and the
other directors to be designated by the parties will be included in the Schedule
14(f)-1 Notice to Stockholders which will be filed with the SEC and mailed to
stockholders at least ten (10) days prior to the Closing of the Exchange.

      At or prior to the Closing, Chiste will also enter into a certain
financial advisory agreement with Keating Securities, LLC ("Keating
Securities"), a registered broker-dealer, under which Keating Securities will be
compensated by Chiste for its advisory services rendered to Chiste in connection
with the Exchange. The transaction advisory fee will be $325,000, with the
payment thereof being subject to the Closing of the Exchange.

      Each of Chiste and HydroGen has agreed to continue to operate their
business in the ordinary course prior to the Exchange. In addition, HydroGen is
able to pursue the Placement and take the actions necessary to effect the
Exchange and Chiste is able to pursue the Investment.

      Under the Exchange Agreement, each of Chiste and HydroGen has agreed to do
certain things, some of which are conditions to the exchange transaction. Each
company is obligated to (a) obtain all necessary approvals, which includes
approval by the members of HydroGen for various aspects of the transaction, (b)
HydroGen is required to obtain agreements from its members to exchange their
Interests and to amend all outstanding agreements to acquire Interests to
substitute shares of Preferred Stock or common stock of Chiste in connection
with any options, warrants and convertible securities and other agreements, (c)
HydroGen must enter into agreements to eliminate any existing pre-emptive rights
for Interests, (d) give the other access to the records and personnel to
complete due diligence review, (e) proceed expeditiously to undertake all
actions so as to be able to consummate the Exchange, (d) HydroGen must deliver
audited financial statements including a balance sheet as of December 31, 2004
and statements of operations, cash flows and stockholders' equity from inception
to December 31, 2004 and unaudited financial statements of HydroGen for the
quarter ended prior to the Closing, and (e) neither party will solicit or
initiate proposals from, provide information to or hold discussions with any
party concerning any sale of assets or any material portion of any capital stock
or any merger, consolidation, business combination, liquidation or similar
transaction, subject to the fiduciary obligations of directors generally.

                                       5
Consummation of the Exchange is conditioned upon the minimum amount of the
Placement being held in escrow and available at the time of the consummation of
the Exchange. Consummation of the Exchange is also contingent upon tax counsel
to HydroGen issuing its opinion that the transaction will not be taxable to the
holders of Interests (including the Interests sold in the Placement) pursuant to
Section 351 of the Internal Revenue Code. Hydrogen also will have entered into
employment agreements with its senior executives. The management persons will
have entered into a voting agreement, similar to that agreed to by the HydroGen
Investors in the Placement, to vote in favor of the Actions following the
Exchange and for the KRM Designate for a period of one year after the closing of
the Exchange. In addition to the foregoing conditions, the Exchange is
conditioned upon (i) preparation, filing and distribution to the Chiste
stockholders of a Schedule 14(f)-1 Notice to Stockholders, and (ii) continued
quotation of Chiste's common stock on the Over-the-Counter Bulletin Board.

      Except for the representations and warranties relating to the ownership of
the Interests (including the Interests sold in the Placement) which survive the
consummation of the Exchange, the representations and warranties of all the
parties to the Exchange Agreement do not survive the closing.

      The Exchange Agreement may be terminated as follows: (i) by mutual
consent, (ii) by either party if the Exchange is not consummated by June 15,
2005, (iii) by either party if the Exchange is prohibited by issuance of an
order, decree or ruling, (iv) by either party if the other is in material breach
of any representation, warranty, covenant or agreement, or (v) by Chiste if
HydroGen is not able to obtain the agreement of each HydroGen Member and each
HydroGen Investor to join in the Exchange Agreement and agree to transfer their
Interests to Chiste in the Exchange. In the event of termination, both parties
are responsible for their expenses, except that Chiste may retain a $50,000
deposit paid by HydroGen in the event that the termination is for a breach by
HydroGen or failure to obtain the agreement of all of the HydroGen Members to
join in the Exchange Agreement or convey their Interests.

      Because an integral part of the Exchange and a condition to the Placement
is the completion of the Investment in the Preferred Stock by the Institutional
Investors, which itself is contingent on the consummation of the Exchange and
the minimum amount being received under the Placement in escrow, the Investment
will be made after the Closing of the Exchange. The Investment must be
subscribed and funded within three days of the Closing of the Exchange. If the
Institutional Investors do not subscribe for $7,000,000 of Preferred Shares and
fund the subscription within such three day period, then the Exchange will be
rescinded, and the Placement cancelled with the escrowed subscriptions for
Interests returned to the HydroGen Investors, without interest or deduction.
Additionally, in the event of a rescission of the Exchange, all other aspects of
the Exchange will be cancelled and the HydroGen Members restored to their
relative ownership and positions in HydroGen and of Interests in HydroGen as it
was immediately prior to the Exchange.

      The directors of Chiste have approved the Exchange Agreement and the
transactions contemplated thereunder. The managers of HydroGen have approved the
Exchange Agreement and the transactions contemplated thereunder, and members
owning approximately 69.7% of HydroGen's outstanding Interests have executed the
Exchange Agreement . The parties expect the closing of the transactions under
the Exchange Agreement to occur on or about June 15, 2005. However, there can be
no assurances that the Exchange will be completed.

                                       6
On March 28, 2005, in its Current Report on Form 8-K dated March 24, 2005,
Chiste reported the execution of a letter of intent to acquire HydroGen.

      Kevin R. Keating is the father of the principal member of Keating
Investments, LLC. Keating Investments, LLC is the managing member of KRM Fund,
which is the current majority stockholder of Chiste, and Keating Securities,
LLC, the registered broker-dealer affiliate of Keating Investments, LLC. Kevin
R. Keating is not affiliated with and has no equity interest in Keating
Investments, LLC, KRM Fund or Keating Securities, LLC and disclaims any
beneficial interest in the shares of Chiste's common stock owned by KRM Fund.
Similarly, Keating Investments, LLC, KRM Fund and Keating Securities, LLC
disclaim any beneficial interest in the shares of Chiste's common stock
currently owned by Kevin R. Keating.

Business of Chiste

      Chiste is currently a public "shell" company with nominal assets whose
sole business has been to identify, evaluate and investigate various companies
with the intent that, if such investigation warrants, a reverse merger
transaction be negotiated and completed pursuant to which Chiste would acquire a
target company with an operating business with the intent of continuing the
acquired company's business as a publicly held entity.

Business of HydroGen

      HydroGen is a development stage company, organized in 2001 and established
as a limited liability company in January 2002. One of the founding members
contributed various intellectual property assets and technologies which it had
acquired from Westinghouse Electric Corporation, some of which were developed
under a Department of Energy (DOE) sponsored research and development program.

      HydroGen was established to be a developer of multi-megawatt fuel cell
systems utilizing its proprietary 400 kilowatt (kW) phosphoric acid fuel cell
(PAFC) technology. HydroGen is positioning itself to compete in the rapidly
growing distributed generation market, by offering complete fuel cell systems in
the 6-30 megawatt (MW) range at prices that HydroGen's management believes will
be competitive with incumbent generating technologies in this size class, and
significantly lower than other fuel cell technologies.

      HydroGen's technology and approach are unique because air-cooled PAFC fuel
cells are used, and the individual fuel cell stacks are detached from the
hydrogen source. HydroGen's management believes this approach will result in
significant cost savings, since air-cooled stacks are inherently simple to
manufacture, and because HydroGen's fuel cell power plants can utilize either
mature, large-scale hydrogen plant technology or existing hydrogen
infrastructure to supply hydrogen to the fuel cell stacks.

                                       7
HydroGen's products provide close to zero-emission, net water-generating,
reliable, high-quality electric power from hydrogen. These products address
directly the problems associated with the current inefficient, centralized,
combustion-based energy system by offering economically competitive fuel cell
systems that will accelerate market entry of the "hydrogen economy."

      Target markets for HydroGen systems include the general industrial
cogeneration market, grid support and distributed generation for utilities,
educational and municipal institutions seeking clean power, and niche markets
associated with the existing global hydrogen production infrastructure. HydroGen
has done extensive market research, supported in part by the DOE, and is working
in partnership with major industrial gas companies, utilities, chemicals
companies, and select government facilities to identify project locations for
HydroGen's early series of units.

      Hydrogen's intellectual property includes certain rights and manufacturing
assets for the 400 kW, air-cooled PAFC technology developed by Westinghouse and
represented by a revocable, non-exclusive license to use all technology
developed pursuant to the DOE sponsored program. In addition, Westinghouse
undertook its own development of module designs and manufacturing plans, and
constructed a manufacturing facility and working prototype module. During this
manufacturing and prototype program, Westinghouse privately developed recipes,
processes and plans for designing and manufacturing phosphoric acid fuel cells.
That intellectual property, maintained by Westinghouse as trade secrets, has
been transferred to the HydroGen along with all of Westinghouse's rights to the
technology developed under the DOE research and development program, and has
since been maintained as closely held secrets.

      Most of HydroGen's core intellectual property has been maintained as trade
secrets, which are kept in the form of drawings, recipes, process descriptions
and other writings. HydroGen has kept, and intends to continue to keep, these
secrets closely guarded, distributing them on a need to know basis only, and
implementing strict confidentiality and non-use agreements when disclosure is
necessary.

      Although most of the core technology has been maintained as trade secrets,
Westinghouse applied for and received patents from time to time related to the
technologies. These were all subsequently assigned to the DOE. A non-exclusive
license to use these patents has been assigned, to HydroGen. Although, most of
the DOE patents have expired or were allowed by the DOE to lapse, the DOE did
maintain four key patents, which remain in effect today. HydroGen has submitted
an application to the DOE for an exclusive license for the continuing patents.
The application is now under DOE review, which review includes a 30 day public
comment period before the DOE can grant the exclusive license. If the DOE is
unable to grant the exclusive license, HydroGen will be able to continued use
the patents on a non-exclusive, licensed basis.

      HydroGen occupies approximately 30,000 square feet of manufacturing
facilities in Jefferson Hills, PA (near Pittsburgh), and operates them as its
pilot manufacturing plant. Hydrogen intends to use some of the capital it
proposes to raise to increase the production capacity of this facility from the
current 2MW/year capacity to 4-5 MW/year. The facility includes production
equipment for the electrodes, graphite plates, stacks, and various non-repeating
components of the fuel cells and fuel cell stacks. The long-term plan is to
expand production by deploying an automated manufacturing plant capable
initially of producing 25MW (62 modules) per year, and later 100MW (250 modules)
per year.

                                       8
HydroGen's business model is to sell on a turnkey basis 6-30MW power
plants, based on a standardized 2MW power island consisting of five of its 400kW
modules. Additionally, HydroGen plans to generate recurring revenues from the
sale of operations and maintenance services and ongoing lease revenues for the
400kW modules which must be replaced every 40,000 hours initially.

      There are many risks associated with the business of HydroGen, some of
which are indicated below. HydroGen is a development stage company with a
limited operating history on which it may be analyzed. HydroGen will be exposed
to all the risks of establishing a new business in a developmental field,
including finding appropriate personnel, managing development of its products
and marketing efforts, and managing its capital resources and future funding.
The intellectual property rights held by Hydrogen may require additional
development which may require additional unplanned expense, and solving
unanticipated engineering problems. HydroGen does not have experience in
manufacturing fuel cell power plants on a commercial basis, and therefore, it
may not be able to achieve market driven production standards and production
volumes required to operate cost effectively. The principal intellectual
property rights were developed by Westinghouse and the DOE, and there are some
uncertainties as to the sufficiency and scope of those rights evidenced in the
change of assignments and licenses. Others may assert interests in the HydroGen
intellectual property rights which may impede or limit HydroGen's ability to
capitalize on them. There could be barriers to obtaining customers because
electric utility companies charge fees to industrial customers for disconnecting
from the grid, for using less electricity or using the grid as a backup source.
Because the HydroGen technology is new, it may not be readily accepted in the
market place. HydroGen will require substantial capital to fully develop its
business plan, which capital may not be available in the future or might be
available only on terms that are not economic or subject to many conditions and
limitations. From time to time and for various aspects of its operations,
HydroGen will need to obtain permits and other government approvals which if not
obtained on a timely basis will cause additional costs or limit or prevent
required operations. There is much competition in the energy industry from
conventional sources (i.e. combustion power generation manufacturers and
renewable energy developers) and new alternative technologies (i.e. molten
carbonate fuel cells, solid oxide fuel cells, and biomass energy sources), all
of which will impact on HydroGen's ability to obtain a market presence and win
customers. Any one or more of the above identified risks may affect the business
operations adversely or require capital that may not be available when required,
with the effect of an adverse economic impact on HydroGen and a loss of value in
an investment in the parent holding company.

      Item 9.01 Financial Statements and Exhibits.

      (a) Financial statements of business acquired. None.

      (b) Pro forma financial information. None.

      (c) Exhibits.

          2.2     Exchange Agreement by and between Chiste Corporation,
                  HydroGen, LLC, and certain members of HydroGen, LLC dated May
                  13, 2005.

                                       9
SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934,
Chiste Corporation has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                Chiste Corporation

Date: May 18, 2005            By: /s/ Kevin R. Keating
                                  ---------------------------------------------
                                  Kevin R. Keating, President and Sole Director

                                       10
EXHIBIT INDEX

Exhibit Number                                  Description of Exhibit
--------------                                  ----------------------

     2.2                                   Exchange Agreement by and between
                                           Chiste Corporation, HydroGen, LLC,
                                           and certain members of HydroGen, LLC
                                           dated May 13, 2005.

                                       11